Home Cart Sign in  
Chemical Structure| 1422253-38-0 Chemical Structure| 1422253-38-0

Structure of Foscenvivint
CAS No.: 1422253-38-0

Chemical Structure| 1422253-38-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PRI-724 is a selective inhibitor of the CBP/β-catenin interaction.

Synonyms: PRI-724; C-82 prodrug; ICG-001 analog

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Foscenvivint

CAS No. :1422253-38-0
Formula : C33H35N6O7P
M.W : 658.64
SMILES Code : O=C(N([C@]([C@H](C)N1CC2=C3N=CC=CC3=CC=C2)([H])N4[C@@H](CC5=CC=C(OP(O)(O)=O)C=C5)C1=O)N(C)CC4=O)NCC6=CC=CC=C6
Synonyms :
PRI-724; C-82 prodrug; ICG-001 analog
MDL No. :MFCD12196918
InChI Key :VHOZWHQPEJGPCC-AZXNYEMZSA-N
Pubchem ID :71509318

Safety of Foscenvivint

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Foscenvivint

epigenetics

Isoform Comparison

Biological Activity

Target
  • p300/CBP

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01606579 Acute Myeloid Leukemia ... More >> Chronic Myeloid Leukemia Less << Phase 1 Phase 2 Completed - United States, Georgia ... More >> Emory University / Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Massachusetts University of Massachusetts Medical Center Worcester, Massachusetts, United States, 01655 United States, New Mexico New Mexico Cancer Care Alliance Albuquerque, New Mexico, United States, 87106 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210-1267 United States, Texas University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02195440 Hepatitis C Virus-infected Cir... More >>rhosis Less << PHASE1 COMPLETED 2017-03-31 Tokyo metropolitan Komagome Ho... More >>spital, Tokyo, Japan Less <<
NCT02413853 Colorectal Adenocarcinoma ... More >> Stage IVA Colorectal Cancer Stage IVB Colorectal Cancer Less << Phase 2 Withdrawn(Study drug supply is... More >>sues) Less << November 2018 United States, California ... More >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Less <<
NCT02828254 Hepatitis C Virus-infected Cir... More >>rhosis Less << COMPLETED 2018-01-31 Tokyo metropolitan Komagome Ho... More >>spital, Tokyo, Japan Less <<
NCT01764477 Advanced Pancreatic Cancer|Met... More >>astatic Pancreatic Cancer|Pancreatic Adenocarcinoma Less << PHASE1 COMPLETED 2025-10-15 USC Norris Comprehensive Cance... More >>r Center, Los Angeles, California, 90033, United States|University of California, San Francisco, San Francisco, California, 94115, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States Less <<
NCT03620474 Hepatitis C|Hepatitis B|Liver ... More >>Cirrhoses Less << PHASE1|PHASE2 COMPLETED 2022-02-28 Kohnodai Hospital, National Ce... More >>nter for Global Health and Medicine, Ichikawa, Chiba, 272-8516, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku, Tokyo, 113-8677, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan Less <<
NCT01302405 Advanced Solid Tumors PHASE1 TERMINATED 2025-06-15 Mayo Clinic, Scottsdale, Arizo... More >>na, 85259-5499, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Mayo Clinic, Department of Oncology, Rochester, Minnesota, 55901, United States Less <<
NCT06144086 Liver Cirrhosis PHASE2 ACTIVE_NOT_RECRUITING 2025-06-30 Hokkaido University Hospital, ... More >>Sapporo, Hokkaido, 060-8648, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyo-Ku, Tokyo, 113-8677, Japan|National Hospital Organization Osaka National Hospital, Osaka, 540-0006, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.52mL

0.30mL

0.15mL

7.59mL

1.52mL

0.76mL

15.18mL

3.04mL

1.52mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories